A randomised, double-blind controlled trial of mometosone furoate cream versus placebo to prevent radiation dermatitis of the breast and chest wall

ISRCTN ISRCTN03885092
DOI https://doi.org/10.1186/ISRCTN03885092
EudraCT/CTIS number 2006-002352-15
Secondary identifying numbers 2191
Submission date
07/07/2010
Registration date
07/07/2010
Last edited
24/01/2022
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Signs and Symptoms
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

http://www.cancerhelp.org.uk/trials/a-trial-effect-using-steroid-cream-decrease-skin-reactions-caused-having-radiotherapy

Contact information

Ms Helen Spickett
Scientific

Rosemere Cancer Centre
Royal Preston Hospital
Sharoe Green Lane
Fulwood
Preston
PR2 9HT
United Kingdom

Email helen.spickett@lsccn.nhs.uk

Study information

Study designSingle centre randomised interventional process of care trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeDiagnostic
Scientific titleA randomised, double-blind controlled trial of mometosone furoate cream versus placebo to prevent radiation dermatitis of the breast and chest wall
Study acronymSkin Study
Study objectivesA prospective, double blind, randomised study investigating the effect of mometasone furoate on the prevention of radiation dermatitis of the breast and chest wall. Scoring systems include visual scoring and reflectance spectrometry. Participants receiving a 40 Gy, 15 fractionated, 3 week radical course of whole breast radiotherapy plus or minus breast boost will be eligible.
Ethics approval(s)MREC approved (ref: 06/Q0201/79)
Health condition(s) or problem(s) studiedTopic: National Cancer Research Network; Subtopic: Breast Cancer; Disease: Breast
InterventionPlacebo or mometasone furoate. Assessments are taken at baseline, day 8, 15, 21, 29, 36 and 43.

Study entry: single randomisation only
Intervention typeDrug
Pharmaceutical study type(s)
PhasePhase III
Drug / device / biological / vaccine name(s)Mometasone furoate
Primary outcome measureChange in visual skin assessment
Secondary outcome measures1. Objective skin assessment
2. Changes in quality of life measures
Overall study start date02/11/2009
Completion date31/07/2011

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participantsPlanned sample size: 120; UK sample size: 120
Key inclusion criteria1. Aged 18 years or over, either sex
2. Receiving 40 Gy 15 fractionated, 3 week radical radiotherapy to the breast or chest wall
3. Patient provides informed consent to participate in the study and completes follow up
Key exclusion criteria1. Skin involvement of disease
2. Untreated bacterial, fungal or viral skin lesions
3. Inability to self administer creams
Date of first enrolment02/11/2009
Date of final enrolment31/07/2011

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Rosemere Cancer Centre
Preston
PR2 9HT
United Kingdom

Sponsor information

Lancashire Teaching Hospitals NHS Trust (UK)
Hospital/treatment centre

Royal Preston Hospital
Sharoe Green Lane
Fulwood
Preston
PR2 9HT
England
United Kingdom

Website http://www.lancsteachinghospitals.nhs.uk/
ROR logo "ROR" https://ror.org/02j7n9748

Funders

Funder type

Charity

Rosemere Cancer Foundation (UK)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing planNot provided at time of registration

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Plain English results 24/01/2022 No Yes
Results article 15/11/2014 24/01/2022 Yes No

Editorial Notes

24/01/2022: The following changes were made to the trial record:
1. A link to plain English results was added.
2. Publication reference added.
14/03/2017: No publications found in PubMed, verifying study status with principal investigator
17/02/2011: The anticipated end date for this trial has been updated from 01/01/2010 to 31/07/2011.